The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer

Colorectal Disease

Volumn 16, Issue 4, 2014, Pages

  Bhangu, A ^a,b   Wood, G ^c   Brown, G ^a   Darzi, A ^c   Tekkis, P ^a,b   Goldin, R ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Colorectal cancer; E cadherin; Epithelial mesenchymal transition; Micro RNA 200; Rectal cancer; Tumour budding

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; MICRORNA 200C; UVOMORULIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RESISTANCE; CANCER SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; RECTUM RESECTION; TREATMENT RESPONSE; TUMOR INVASION;

COLORECTAL CANCER; E-CADHERIN; EPITHELIAL MESENCHYMAL TRANSITION; MICRO-RNA 200; RECTAL CANCER; TUMOUR BUDDING;

AGED; BETA CATENIN; CADHERINS; CHEMORADIOTHERAPY, ADJUVANT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84896054725     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12482     Document Type: Article

References (35)

1. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998; 133: 894-9.
2. van Gijn W, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-82.
3. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644-50.
4. Pettersson D, Cedermark B, Holm T et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010; 97: 580-7.
5. Bosset JF, Calais G, Mineur L et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results-EORTC 22921. J Clin Oncol 2005; 23: 5620-7.
6. Castaldo ET, Parikh AA, Pinson CW, Feurer ID, Merchant NB. Improvement of survival with response to neoadjuvant radiation therapy for rectal cancer. Arch Surg 2009;144:129-34; discussion 34-5.
7. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R. Epithelial mesenchymal transition in colorectal cancer: seminal role in promoting disease progression and resistance to neoadjuvant therapy. Surg Oncol 2012; 21: 316-23.
8. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-8.
9. Kahlert C, Klupp F, Brand K et al. Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci 2011; 1: 1349-7006.
10. Long J, Zhang Y, Yu X et al. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011; 15: 817-28.
11. Nicolini A, Ferrari P, Fini M et al. Stem cells: their role in breast cancer development and resistance to treatment. Curr Pharm Biotechnol 2011; 12: 196-205.
12. Hur K, Toiyama Y, Takahashi M et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 62:1315-26.
13. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-6.
14. The Royal College of Pathologists. Dataset for Colorectal Cancer, 2nd Edition. London. http://www.rcpath.org/Resources/RCPath/Migrated%20Resources/Documents/G/G049-ColorectalDataset-Sep07.pdf. (accessed December 2012).
15. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010; 28: 264-71.
16. Puppa G, Senore C, Sheahan K et al. Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology 2012; 61: 562-75.
17. Jorgensen S, Baker A, Moller S, Nielsen BS. Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. Methods 2010; 52: 375-81.
18. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000; 87: 992-1005.
19. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1: 651-61.
20. Kurrey NK, Jalgaonkar SP, Joglekar AV et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27: 2059-68.
21. Du Z, Qin R, Wei C et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig Dis Sci 2011; 56: 741-50.
22. Zhang S, Wang X, Osunkoya AO et al. EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene 2011; 30: 30.
23. Shintani Y, Okimura A, Sato K et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg 2011;92:1794-804; discussion 804.
24. Yang AD, Fan F, Camp ER et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12: 4147-53.
25. Kawamoto A, Yokoe T, Tanaka K et al. Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep 2012; 27: 51-7.
26. Edden Y, Wexner SD, Berho M. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma. Colorectal Dis 2012; 14: 555-61.
27. Toiyama Y, Inoue Y, Saigusa S et al. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery. Clin Oncol (R Coll Radiol) 2010; 22: 272-80.
28. Zlobec I, Vuong T, Compton CC et al. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 2008; 98: 450-6.
29. Zlobec I, Terracciano L, Tornillo L et al. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut 2008; 57: 1413-9.
30. Du C, Xue W, Li J, Cai Y, Gu J. Morphology and prognostic value of tumor budding in rectal cancer after neoadjuvant radiotherapy. Hum Pathol 2012; 43: 1061-7.
31. Kawamoto A, Yokoe T, Tanaka K et al. Radiation induces epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep 2012; 27: 51-7.
32. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010; 9: 3807-14.
33. Okamoto A, Shirakawa T, Bito T et al. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology 2008; 71: 156-60.
34. Adhim Z, Matsuoka T, Bito T et al. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer 2011; 105: 393-402.
35. Baron JA, Sandler RS, Bresalier RS et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-82.